title: Ornithine alpha-ketoglutarate metabolism after enteral administration in burn patients: bolus compared with continuous infusion.
abstract: Ornithine alpha-ketoglutarate (OKG) has been successfully used as an enteral supplement in the treatment of catabolic states, including burn injury. However, specific questions remain unanswered concerning burn patients, including OKG metabolism and metabolite production, appropriate mode of administration, and dose. We thus performed a kinetic study and followed plasma ornithine and OKG metabolite concentrations on day 7 postburn in 42 (35 men, 7 women) consecutive burn patients aged 33 +/- 2 y with a mean (+/-SEM) total burn surface area (TBSA) of 31 +/- 1%. Patients were randomly assigned to receive OKG as a single bolus (10 g; n = 13) or in the form of a continuous gastric infusion (10, 20, or 30 g/d over 21 h; n = 13) or an isonitrogenous control (n = 16). Plasma pharmacokinetics of ornithine followed a one-compartment model with first-order input (r = 0.993, P < 0.005). OKG was extensively metabolized in these patients (absorption constant = 0.028 min-1, elimination half-life = 89 min), with the production of glutamine, arginine, and proline; proline was quantitatively the main metabolite [in OKG bolus, area under the curve (AUC)0-7h: proline, 41.4 +/- 5.6 mmol.min/L; glutamine, 20.4 +/- 5.7 mmol.min/L; and arginine, 7.3 +/- 1.9 mmol.min/L]. Proline production was dose-dependent and quantitatively similar between modes of OKG administration. Glutamine and arginine production were not dose-dependent and were higher in the bolus group than in the infusion group. Overall, the bolus mode of OKG administration appeared to be associated with higher metabolite production compared with continuous infusion in burn patients, especially for glutamine and arginine.
authors.affiliation: Service de Biochimie A, Hôpital St-Antoine, Paris, France.
authors.forename: T
authors.initials: T
authors.lastname: Le Bricon
authors.forename: C
authors.initials: C
authors.lastname: Coudray-Lucas
authors.forename: N
authors.initials: N
authors.lastname: Lioret
authors.forename: S K
authors.initials: SK
authors.lastname: Lim
authors.forename: F
authors.initials: F
authors.lastname: Plassart
authors.forename: L
authors.initials: L
authors.lastname: Schlegel
authors.forename: J P
authors.initials: JP
authors.lastname: De Bandt
authors.forename: R
authors.initials: R
authors.lastname: Saizy
authors.forename: J
authors.initials: J
authors.lastname: Giboudeau
authors.forename: L
authors.initials: L
authors.lastname: Cynober
mesh_terms: D000328:Adult; D001120:Arginine / Q000097:blood; D002056:Burns / Q000378:metabolism*; D004750:Enteral Nutrition; D005260:Female; D006207:Half-Life; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D009952:Ornithine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood* / Q000378:metabolism / Q000493:pharmacokinetics*; D011897:Random Allocation
chemical_list: C002118:ornithine alpha-ketoglutarate; D001120:Arginine; D009952:Ornithine